Indications of Flupentixol and Melitracen
The combination of flupentixol and melitracen is primarily indicated for depression and anxiety disorders, though it has emerging evidence for off-label use in refractory chronic cough, functional gastrointestinal disorders (particularly diarrhea-predominant IBS and epigastric pain syndrome), persistent idiopathic facial pain, and aerophagia.
FDA-Approved Indication
The FDA labeling for flupentixol indicates its use for chronic schizophrenia requiring prolonged parenteral neuroleptic therapy 1. However, this refers to flupentixol decanoate injection as a monotherapy antipsychotic, not the oral combination with melitracen.
Important caveat: The provided FDA labels for "melitracen" 2 are actually describing mexiletine (an antiarrhythmic), which is a data error and should be disregarded entirely.
Primary Clinical Use
The flupentixol-melitracen combination (typically 0.5 mg flupentixol + 10 mg melitracen per tablet) functions as:
- Flupentixol: Low-dose dopamine receptor antagonist with anxiolytic properties
- Melitracen: Tricyclic antidepressant with noradrenaline/serotonin reuptake inhibition
This combination is primarily prescribed for depression with anxiety and somatoform disorders in many countries outside the United States.
Emerging Evidence-Based Indications
Refractory Chronic Cough
The strongest recent evidence supports use in refractory chronic cough unresponsive to neuromodulators. A 2025 randomized, double-blind, placebo-controlled trial demonstrated that flupentixol-melitracen (one tablet twice daily for 2 weeks) achieved a 65.3% cough resolution rate versus 32.0% with placebo (p=0.0009) 3. This represents a clinically meaningful benefit in patients who had already failed at least 2 weeks of other neuromodulator therapy.
Functional Gastrointestinal Disorders
For diarrhea-predominant IBS (IBS-D): A 2019 meta-analysis of 15 RCTs (n=1487) showed that pinaverium bromide combined with flupentixol-melitracen was superior to pinaverium alone (OR=5.17,95%CI 3.79-7.07, p<0.00001) for symptom relief, with no significant difference in adverse events 4.
For epigastric pain syndrome (EPS): A 2025 trial in female patients demonstrated improvement in dyspepsia symptoms, somatization, and even urinary inflammatory indicators when FM was added to omeprazole 5. Another 2020 study showed that esomeprazole plus flupentixol-melitracen improved erosive gastritis symptoms and reduced recurrence compared to esomeprazole alone 6.
Aerophagia
A 2025 randomized controlled trial (n=90) found that flupentixol-melitracen alone or combined with itopride significantly improved aerophagia symptoms compared to itopride alone (VAS improvement scores: 6.92±2.96 vs 4.58±4.08, p=0.016) 7.
Persistent Idiopathic Facial Pain (PIFP)
A 2024 retrospective study (n=128) reported an 82% pain relief rate (≥50% NRS reduction) with flupentixol-melitracen at doses ≥4 tablets daily, with median onset at 3 days 8. Earlier treatment after diagnosis correlated with better outcomes, suggesting this should be considered early rather than as a last resort.
Dosing Pattern Across Indications
The typical regimen is:
- Standard dose: 1 tablet (0.5mg/10mg) twice daily
- Higher dose for pain: Up to 4+ tablets daily for PIFP 8
- Duration: 2-4 weeks for acute treatment, with some conditions requiring longer maintenance
Safety Profile
Across all studies, adverse events were predominantly mild and included:
- Drowsiness/sedation
- Dry mouth
- Dizziness
- Gastrointestinal symptoms
No serious adverse events or treatment-related deaths were reported in the controlled trials 3, 7, 8. Discontinuation rates due to side effects were low, and symptoms resolved after stopping the medication.
Clinical Decision Algorithm
First-line consideration: Depression with anxiety, somatoform disorders with prominent anxiety
Second-line/adjunctive use:
- Refractory chronic cough after failed neuromodulator trial (≥2 weeks)
- IBS-D with significant anxiety/depression component (combine with prokinetic)
- Functional dyspepsia/EPS with somatization (combine with PPI)
- Persistent idiopathic facial pain (consider early, especially if pain duration <6 months)
- Aerophagia refractory to prokinetics alone
Treatment duration: Start with 2-4 week trial; assess response and continue if beneficial
Key pitfall to avoid: Do not confuse this combination with high-dose antipsychotic flupentixol used for schizophrenia—the doses and indications are entirely different.